Yes, I should have been clearer - obviously the FDA is concerned about preclinical signals of any compound under review. But in this case, we are talking about a signal from a knockout animal model. So that raises only a theoretical concern that I don't think the FDA would normally concern itself with.
But it does make me personally more cautious about the pathway in the long term.
Market Data 
Markets 
AI
